10032925Accelerating the discovery of next-generation cancer therapeutics through exploring protein fitness landscapes using a machine learning-driven evolution engineClosedCollaborative R&DInnovate UKLabGenius uses robotic automation, synthetic biology and advanced machine learning to explore protein fitness landscapes and improve multiple drug properties simultaneously. LabGenius' mission is to accelerate the discovery of next-generation therapeutic antibodies by pioneering the development of a smart robotic platform ('EVA') that is capable of designing, conducting and, critically, learning from its own experiments. The current **state-of-the-art** is sequential optimisation, which takes a long time and is less effective. No-one else is currently using a data-led approach to TCE optimisation and LabGenius' highly multidisciplinary team of data-scientists alongside the robotics set-up are well ahead of others' capabilities. However, they are currently not able to optimise T-cell engaging domains because large amounts of data (gathered in-house, drawing heavily on team and resources) are required for training and developing this capability.